You Lü

12.0k citations
263 papers · 7.0k indexed · 2 hit papers · h-index 41

You Lü

255 papers receiving 7.0k citations

Hit Papers

Nivolumab Versus Docetaxel...2652004202620112018250500750

Peers

You Lü
Comparison fields: 5 of 127
  • Oncology 2.9k
  • Pulmonary and Respiratory Medicine 2.6k
  • Cancer Research 1.0k
  • Genetics 1.3k
  • Molecular Biology 2.6k
Replace Ossama Tawfik with:
Ossama Tawfik United States
Sybren L. Meijer Netherlands
Bhaskar Kallakury United States
Shunsuke Kagawa Japan
Emina H. Huang United States
Harry Hollema Netherlands
Kenneth E. Lipson United States
Alain C. Mita United States
P. Schlag Germany
Toshiyoshi Fujiwara Japan
You Lü relative to Ossama Tawfik United States Ossama Tawfik's profile →
Citations per field
00.5×3.0×
Ossama Tawfik · 1×
Citations per year

Countries citing papers authored by You Lü

Since Specialization
Citations

This map shows the geographic impact of You Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by You Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites You Lü more than expected).

Fields of papers citing papers by You Lü

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by You Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by You Lü. The network helps show where You Lü may publish in the future.

Co-authorship network

The 25 scholars most cited alongside You Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with You Lü Line = papers co-authored together You Lü links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20250
4 20250
5 20242
6 20241
7 20232
8 20231
9 20234
10 202132
11 20215
12 20201
13 20182
14 201618
15 20151
16 201510
17 20133
18 201356
19 201323
20 200355

About You Lü

You Lü is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 263 papers that have together received 7.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Research Studies (52 papers), Lung Cancer Diagnosis and Treatment (48 papers), Cancer Immunotherapy and Biomarkers (32 papers), Esophageal Cancer Research and Treatment (19 papers), Colorectal Cancer Treatments and Studies (18 papers), Effects of Radiation Exposure (16 papers) and Gastric Cancer Management and Outcomes (15 papers). The work is most often cited by research in Oncology (2.9k citations), Pulmonary and Respiratory Medicine (2.6k citations) and Cancer Research (1.0k citations). You Lü has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Jianxin Xue, Guangping Gao, Roberto Calcedo, James M. Wilson, Mauricio R. Alvira, Luk H. Vandenberghe, Xiangyang Zhou, Lin Zhou, Yi‐Long Wu and Lei Deng. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026